Literature DB >> 18045214

Privileged structures: a useful concept for the rational design of new lead drug candidates.

Carolina D Duarte1, Eliezer J Barreiro, Carlos A M Fraga.   

Abstract

Privileged structures are defined as molecular frameworks which are able of providing useful ligands for more than one type of receptor or enzyme target by judicious structural modifications. In the present work, we describe some examples and applications of the usefulness of the privileged structure concept for the structural design of new drug candidates, by discussing the eligibility of such motifs, including the identification of the N-acylhydrazone template as privileged structures.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18045214     DOI： 10.2174/138955707782331722

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  41 in total

1.  Synthesis and diversification of 1,2,3-triazole-fused 1,4-benzodiazepine scaffolds.

Authors:  James R Donald; Stephen F Martin
Journal:  Org Lett       Date:  2011-01-28       Impact factor: 6.005

2.  Application of a sequential multicomponent assembly process/huisgen cycloaddition strategy to the preparation of libraries of 1,2,3-triazole-fused 1,4-benzodiazepines.

Authors:  James R Donald; Rebekah R Wood; Stephen F Martin
Journal:  ACS Comb Sci       Date:  2012-02-01       Impact factor: 3.784

3.  An integrated drug-likeness study for bicyclic privileged structures: from physicochemical properties to in vitro ADME properties.

Authors:  Chunyan Han; Jinlan Zhang; Mingyue Zheng; Yao Xiao; Yan Li; Gang Liu
Journal:  Mol Divers       Date:  2011-05-03       Impact factor: 2.943

4.  Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting.

Authors:  Feng Zhu; Chu Qin; Lin Tao; Xin Liu; Zhe Shi; Xiaohua Ma; Jia Jia; Ying Tan; Cheng Cui; Jinshun Lin; Chunyan Tan; Yuyang Jiang; Yuzong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

Review 5.  Chalcone: A Privileged Structure in Medicinal Chemistry.

Authors:  Chunlin Zhuang; Wen Zhang; Chunquan Sheng; Wannian Zhang; Chengguo Xing; Zhenyuan Miao
Journal:  Chem Rev       Date:  2017-05-10       Impact factor: 60.622

6.  1,4-Thienodiazepine-2,5-diones via MCR (II): scaffold hopping by Gewald and Ugi-deprotection-cyclization strategy.

Authors:  Yijun Huang; Alexander Dömling
Journal:  Chem Biol Drug Des       Date:  2010-06-09       Impact factor: 2.817

7.  Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei.

Authors:  Darren W Begley; Robert C Hartley; Douglas R Davies; Thomas E Edwards; Jess T Leonard; Jan Abendroth; Courtney A Burris; Janhavi Bhandari; Peter J Myler; Bart L Staker; Lance J Stewart
Journal:  J Struct Funct Genomics       Date:  2011-02-26

8.  Multicomponent synthesis of diverse 1,4-benzodiazepine scaffolds.

Authors:  Yijun Huang; Kareem Khoury; Tyler Chanas; Alexander Dömling
Journal:  Org Lett       Date:  2012-11-16       Impact factor: 6.005

9.  Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.

Authors:  Jitesh R Shah; Philip D Mosier; Bryan L Roth; Glen E Kellogg; Richard B Westkaemper
Journal:  Bioorg Med Chem       Date:  2009-08-13       Impact factor: 3.641

10.  Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.

Authors:  Douglas R Davies; Bjorn Mamat; Olafur T Magnusson; Jeff Christensen; Magnus H Haraldsson; Rama Mishra; Brian Pease; Erik Hansen; Jasbir Singh; David Zembower; Hidong Kim; Alex S Kiselyov; Alex B Burgin; Mark E Gurney; Lance J Stewart
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.